Women’s tennis players must take one-time gene test for eligibility

The Women’s Tennis Association (WTA) has announced that all female players will be required to undergo a one-time genetic test to confirm their biological sex, effective starting in 2026. The test will screen for the presence of the SRY gene, which is typically associated with male biological sex. This decision marks a significant shift in the association's eligibility policies, aiming to ensure fair competition among players competing in women’s tournaments. Under the updated rules, players will be required to submit either a cheek swab or blood sample for testing. The policy change comes after the WTA revised its guidelines to address concerns surrounding the participation of transgender athletes in women’s sports. Previously, transgender women were allowed to compete if they declared their gender as female and maintained a reduced testosterone level for two years prior to entering competitions. However, there are currently no known transgender women actively competing at any level within professional tennis. The WTA stated that the screening process will be conducted with strict confidentiality and data privacy measures in place. A comprehensive player engagement program will accompany the implementation of the new policy, ensuring that players receive adequate information and support during the transition. The association emphasized its commitment to treating all players with dignity and handling the situation thoughtfully. This move aligns with broader trends in international sports organizations. In March, the International Olympic Committee (IOC) announced that only biological female athletes, verified through a one-time genetic test, would be eligible to compete in female category events at the Olympics. Similarly, other federations such as World Athletics and World Boxing have introduced similar requirements in recent years. The policy has sparked debate among athletes and advocates. Transgender athlete Renee Richards, who competed on the women’s professional tour from 1977 to 1981, was a pioneering figure in discussions around gender identity in sports. Her legacy continues to influence conversations about inclusivity and fairness. Meanwhile, prominent figures like Martina Navratilova, an 18-time Grand Slam singles champion, have expressed opposition to the inclusion of transgender athletes, arguing that it could create unfair advantages. World number one Aryna Sabalenka has also voiced concerns about the potential impact on competitive fairness. On the other hand, some notable figures, such as Billie Jean King, a 12-time Grand Slam singles champion and winner of the original “battle of the sexes” in 1973, view the exclusion of transgender athletes as discriminatory. King has long advocated for equal opportunities for all individuals, regardless of gender identity. Advocacy groups representing transgender individuals argue that the new policy constitutes discrimination against transgender athletes. They emphasize that transitioning does not fully eliminate the physical advantages gained from male puberty, which can include increased muscle mass and bone density. Critics of transgender inclusion in sports often cite these physiological differences as a basis for their stance. As the WTA prepares to implement its new eligibility criteria, the focus will remain on how the policy is executed and received by players and stakeholders alike. The association has pledged to handle the process with care, balancing the need for fair competition with respect for individual identities. The outcome of this policy will likely shape future discussions on gender and sports participation globally.